LV-CMV-Null-Puro

What it means: CMV is the human cytomegalovirus immediate-early promoter, a strong, constitutive, broadly active viral promoter widely used for high-level transgene expression in many cell lines.

Why it matters:

• The promoter sets where and how strongly the cassette is expressed after transduction.
• CMV can be silenced over time in some cell types (notably stem cells and some in vivo settings).
• Promoter choice also affects how quickly expression appears and whether it persists after weeks in culture or in vivo.

How to interpret here: in LV-CMV-Null-Puro the CMV promoter sits upstream of an empty cassette, so the vector delivers and integrates like the matching transgene vector but produces no transgene product.

Tip: when comparing constructs, keep the promoter constant — differences between CMV and another promoter can be larger than the effect of the transgene itself.

What it means: Constitutive — expression is continuous and not dependent on an inducer or recombinase.

Why it matters:

• No additional reagent or driver line is needed; expression begins after integration and continues in daughter cells.
• No inducer, recombinase, driver line or partner construct is needed, which keeps the experiment simple.
• The trade-off is that expression cannot be switched off or timed, so it continues from integration onward in every transduced cell.

How to interpret here: LV-CMV-Null-Puro carries no transgene, so the CMV cassette is empty; what is expressed continuously after integration is the selection marker only.

Tip: this vector IS the matched control: transduce it alongside the transgene-expressing vector at the same MOI so backbone, transduction and selection effects can be subtracted.

What it means: Puromycin — puromycin N-acetyltransferase (pac) confers resistance to puromycin.

Why it matters:

• Puromycin kills non-transduced mammalian cells quickly, typically within a few days, so stable pools can be selected rapidly.
• The marker decides whether stable pools can be drug-selected and which other markers can be combined in the same cells.
• Selection also removes the untransduced fraction, which simplifies downstream assays that require a uniform population.

How to interpret here: the selection marker for this vector is Puromycin; drug-resistant survivors are the cells that carry the integrated cassette.

Tip: titrate Puromycin on the target cells first (kill curve) — the effective dose varies widely between cell types.

What it means: >1E+9 TU/mL is the functional titer in transducing units (TU) per mL — the concentration of vector particles able to transduce and integrate into target cells.

Why it matters:

• Functional titer is what determines the multiplicity of infection (MOI) you can reach with a given volume.
• The value is stated as a minimum (>1E+9 TU/mL), so treat it as a floor when planning volumes rather than as an exact content figure.
• Functional titers are assay-dependent, so compare titers between vendors only when the titration method is the same.

How to interpret here: calculate MOI from >1E+9 TU/mL and your cell number; optimize MOI per cell type, since transduction efficiency differs between lines and primary cells.

Tip: keep the vector cold during dilution and avoid vortexing — titer loss from repeated freeze-thaw or rough handling is the most common reason a >1E+9 TU/mL stock underperforms.

What it means: BSL-2 is the biosafety containment level required for handling this lentiviral vector.

Why it matters:

• BSL-2 work requires a certified biosafety cabinet, appropriate PPE and decontamination of all waste and surfaces.
• Institutional biosafety approval is usually required before lentiviral work begins, and transfer between labs follows the same containment rules.
• Transduced cells and used media remain BSL-2 material until decontaminated.

How to interpret here: handle LV-CMV-Null-Puro under BSL-2 practices throughout storage, thawing, transduction and disposal.

Tip: check whether your institution requires enhanced BSL-2 practices for lentiviral vectors carrying particular transgenes; this varies between institutions.